The Food and Drug Administration Friday updated its emergency use authorizations for two intravenous infusion therapies for outpatients at risk for progressing to severe COVID-19 disease. Specifically, it updated the patient selection criteria and safety summary for the monoclonal antibodies bamlanivimab and etesevimab administered together, and the patient selection criteria for the monoclonal antibodies casirivimab with imdevimab (REGEN-CON) administered together. For details on the changes, see the FDA fact sheets for bamlanivimab and etesevimab and REGEN-COV.  

Related News Articles

Headline
The AHA, America’s Essential Hospitals, Association of American Medical Colleges, Catholic Health Association of the United States, and Children’s Hospital…
Headline
The Centers for Disease Control and Prevention today adjusted its guidance for fully vaccinated individuals, urging indoor masking in states that are labeled…
Headline
The Health Resources and Services Administration today awarded 127 organizations a total of $121 million in American Rescue Plan Act funds to work with…
Headline
The Food and Drug Administration last week issued an emergency use authorization to Becton, Dickinson and Company for its sodium citrate blood specimen…
Headline
Some individuals with “long COVID” may have a disability under Section 1557 of the Affordable Care Act and other civil rights laws that entitles them to…
Headline
The Federal Emergency Management Agency Friday released an advisory on reimbursable communications and outreach expenses for nonprofit medical facilities and…